Compounded Peptides: What You Need to Know

503A vs 503B Compounding Pharmacies

Compounded drugs in the United States are primarily prepared by two types of pharmacies, each operating under different regulatory frameworks:

• 503A Pharmacies are traditional compounding pharmacies that prepare medications based on individual patient prescriptions. They are regulated primarily at the state level and are exempt from certain FDA requirements, including current Good Manufacturing Practice (cGMP) standards. They typically serve patients one at a time.
• 503B Outsourcing Facilities are registered with the FDA and can produce compounded drugs in larger quantities without individual patient prescriptions. They must comply with cGMP standards, report adverse events, and undergo FDA inspections. They offer a higher level of quality oversight compared to 503A pharmacies.

FDA Position on Compounded Semaglutide Salts

The FDA has taken the position that semaglutide sodium, a salt form used by some compounding pharmacies, is not the same as the FDA-approved semaglutide base. The agency has issued warnings that compounded versions of semaglutide may pose risks due to differences in the active ingredient form, potential impurities, and lack of standardized manufacturing.

Patients who receive compounded semaglutide should understand that these products have not undergone the same testing as Ozempic, Wegovy, or Rybelsus, and adverse event reporting may be limited.

Shortage-Based Compounding Rules

Under federal law, compounding pharmacies may prepare copies of FDA-approved drugs during officially declared drug shortages. The FDA maintains a drug shortage database, and when a drug like tirzepatide or semaglutide appears on it, compounders may legally prepare versions. However, once the shortage is resolved, this exception typically ends. Patients should verify current shortage status with their pharmacy and prescriber.

Dosing Error Risks

Compounded peptides may carry elevated risks for dosing errors. Unlike FDA-approved products with standardized concentrations and delivery devices, compounded preparations may vary in concentration, volume, and injection device. The FDA has documented cases of adverse events linked to incorrect dosing of compounded peptide products, including hospitalizations. Patients should always confirm concentration and dosing instructions with their prescriber and pharmacist.